A large AI-driven review of Reddit posts suggests that users of GLP-1 therapies like semaglutide and tirzepatide report symptoms not always captured in clinical trials, prompting calls for closer investigation.
The recent analysis by a team at the University of Pennsylvania turned to public discussion boards to explore what people are reporting while taking GLP-1 medications such as semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (marketed as Mounjaro and Zepbound).
Using artificial intelligence tools, researchers scanned more than 400,000 posts on Reddit written between 2019 and 2026, identifying nearly 70,000 users who said they were taking these drugs. The aim was to surface symptoms and concerns that might not appear in formal trial reports but that matter to patients in day-to-day life.
As expected, many posts described known gastrointestinal effects — for example, the analysis found high rates of nausea (36.9%) and vomiting (16.3%), mirroring clinical trial data. Yet the AI-assisted review also flagged a cluster of less-discussed issues: reports of menstrual irregularities, persistent fatigue, and temperature-related complaints such as hot flushes and chills.
While the study authors emphasize these are signals rather than proven causal links, the volume of unprompted patient reports has generated interest among clinicians and regulators.
Study approach and methodological notes
The team deployed machine learning models to filter, categorize and extract symptom mentions from unstructured conversations across many Reddit threads. By focusing on user self-reports from 2019 to 2026, the study sought to capture the real-world experience of people using these medicines outside controlled trial environments. This approach leverages real-world data and social listening to highlight patterns that formal studies might miss, especially on subjective or quality-of-life issues that participants may emphasize in personal posts.
However, the authors and outside experts caution about limitations intrinsic to public online data. Reddit posts are anonymous and unverifiable, so researchers cannot confirm actual drug exposure, dose, treatment duration or the presence of other medical conditions. There is also no placebo group for comparison, and posters may be more likely to share unusual or severe experiences, introducing reporting bias. These constraints mean the findings are best seen as prompts for targeted clinical research rather than definitive evidence of causation.
What users are reporting
Reproductive and temperature-related complaints
A notable portion of posts referenced changes to menstrual cycles and other reproductive symptoms. Approximately 4% of users who reported side effects mentioned menstrual irregularities such as missed periods, heavier bleeding or spotting between cycles. Temperature-related complaints — including feeling unusually cold, experiencing chills or having hot flushes — were reported in roughly 1–4% of affected users. Researchers theorize these patterns could reflect either direct effects on hormone-regulating centers in the brain or indirect consequences of rapid weight loss and calorie reduction while on therapy.
Fatigue, hair changes and other concerns
Fatigue emerged as a frequent non-gastrointestinal complaint, with about 17% of those reporting adverse experiences describing persistent tiredness. Anecdotes about hair shedding and changes in fertility also appeared, though clinicians point out that rapid weight loss itself can trigger temporary hair loss and changes in menstrual patterns. In many cases, it is difficult to disentangle whether symptoms stem from the medication, the metabolic effects of weight loss, or unrelated health factors.
Implications for patients and clinicians
Researchers stress that these social media signals should encourage open communication rather than alarm. Patients taking GLP-1 therapies are advised to report any new or troubling symptoms to their healthcare provider, who can evaluate dose, duration and other medications or conditions. Clinicians may weigh the overall benefits of weight loss and improved metabolic health against potential side effects, and consider additional monitoring when unexplained reproductive or temperature-related symptoms arise.
Regulators are already observing safety reports for these drugs; for example, national agencies have issued alerts about rare but serious events like pancreatitis and eye-related issues. The Reddit analysis complements formal surveillance by highlighting patient concerns that might warrant focused investigation in prospective studies or updated labeling. Ultimately, the authors describe their work as a starting point: these online patterns are signals that justify more rigorous, controlled research to determine whether a true causal relationship exists.
Conclusion
In short, the AI-driven review of Reddit conversations has amplified patient voices about GLP-1 therapies, bringing attention to symptoms beyond the commonly reported gastrointestinal effects. While the study cannot prove that the drugs caused the reported issues, it underscores the value of combining real-world patient data with traditional research. For people using semaglutide, tirzepatide or related medications, the practical takeaway is simple: monitor symptoms closely, keep an open dialogue with healthcare professionals, and report unusual changes so clinicians and regulators can better understand and manage safety concerns.
